India as a Cosmetic Manufacturing Hub: CDSCO, BIS, and the Regulatory Enablers for Global Manufacturers 

The Strategic Shift 

For most global Cosmetic brands, India’s regulatory journey has begun with import registration — the COS-2 pathway explored throughout this series. But for a growing cohort of global Manufacturers, India is no longer purely an import destination. It is a manufacturing location, an export base, and increasingly, a platform for regional supply chain strategy. 

This shift is being driven by a convergence of market forces: India’s Cosmetic market has crossed USD 6 billion and continues to grow at rates that justify significant supply chain investment; the government’s Make in India creates a favorable backdrop for manufacturing establishment; and the regulatory framework — while detailed — is mature enough to support quality-grade manufacturing at global standards. 

This capstone article explores the regulatory enablers for Cosmetic manufacturing in India, the practical pathways available to global Manufacturers, and what a well-structured market entry strategy looks like when manufacturing is part of the equation. 

The Regulatory Enablers: What Makes India’s Framework Manufacturing-Friendly 

State Licensing Authority (SLA): A Streamlined Manufacturing Gateway 

As detailed in Article 7 of this series, Cosmetic manufacturing licenses in India are issued by State Licensing Authorities — not by a single central authority. This decentralised model creates the opportunity to select a manufacturing state based on a combination of factors: SLA efficiency and processing speed, state-level business incentives, proximity to raw material suppliers, and availability of skilled workforce. 

States such as Himachal Pradesh, Uttarakhand, and Maharashtra have established track records for Cosmetic manufacturing licensing, supported by established industrial clusters and relatively efficient SLA processes. Newer manufacturing destinations in the south and east are increasingly competitive. 

The Loan License (COS-9) Model: Low-Risk Market Entry 

For Manufacturers that are not yet ready to commit to owned facility investment, the COS-9 loan license model provides a regulatory-sanctioned contract manufacturing framework. Under this model, the Manufacturers holds the product formulation, brand, and market registration, while a licensed Indian Cosmetic manufacturer provides the manufacturing facility and GMP compliance infrastructure. 

The COS-9 model allows a global Manufacturers to: 

Assess market demand and distribution channels in India before making significant capital investments in manufacturing facilities. 

Launch an India-manufactured product portfolio, allowing eligible “Made in India” claims on product labels, while establishing local business operations. 

Gradually transition from a loan licence arrangement to their own manufacturing facility as business growth and commercial requirements support the investment. 

GMP Infrastructure: Seventh Schedule as a Quality Baseline 

The GMP requirements under the Seventh Schedule of the Cosmetics Rules 2020 establish a quality manufacturing baseline that is meaningful and auditable. For global Manufacturers whose contract manufacturing partners must meet internal quality standards as well as regulatory requirements, the Seventh Schedule provides a documented regulatory framework against which compliance can be assessed — rather than relying solely on the Manufacturers own supplier quality requirements. 

CDSCO’s Interface with Manufacturing: When Does It Step In? 

A common question from global Manufacturers entering India manufacturing is: if the SLA issues the manufacturing license, what role does CDSCO play for a domestic manufacturer? The answer is nuanced: 

• CDSCO regulates the import of Cosmetics — so if the India-manufactured product is also exported and re-imported, or if import-equivalent routes are involved, CDSCO remains relevant 

• CDSCO governs the approval of new Cosmetic ingredients (COS-3/COS-12) — so if the Indian manufacturing facility produces a product with a novel ingredient, the CDSCO new Cosmetic pathway applies regardless of whether the product is imported or manufactured domestically 

• CDSCO can conduct market surveillance on Cosmetic products in the Indian market — whether imported or domestically manufactured — under the Drugs and Cosmetics Act 

• For products that are manufactured in India and then exported to other markets, the exporting entity must comply with the importing country’s regulatory requirements — and CliniExperts supports this outbound regulatory pathway 

BIS’s Role in Export-Quality Assurance 

BIS standards for Cosmetics are not only a compliance requirement for the Indian market — they serve as a quality infrastructure asset for manufacturing operations targeting export markets. An Indian Cosmetic manufacturing facility that meets BIS Ninth Schedule specifications and maintains ISO-aligned GMP systems is simultaneously positioned to meet the ingredient limit requirements of most ASEAN, GCC, and several other emerging market regulatory frameworks. 

BIS certification of Cosmetic raw materials and intermediates, where available, provides an additional quality signal for export-market regulators reviewing India-origin Cosmetic products. BIS and CDSCO’s ongoing convergence work with international standards bodies further strengthens the credibility of Indian Cosmetic manufacturing on the global stage. 

Make in India for Cosmetics: The Policy Environment 

The Government of India’s Make in India initiative, while primarily associated with sectors like electronics, automotive, and pharmaceuticals in public discourse, has created a broadly favourable environment for Cosmetic manufacturing investment through: 

• State-level industrial policy incentives: capital subsidy schemes, power tariff benefits, and land allocation for manufacturing units in notified industrial areas 

• Ease of Business reforms: the progressive digitisation of regulatory processes (SUGAM portal, SLA portal) and reduction in physical documentation requirements 

• Skilled workforce availability: India has a growing pool of Cosmetic chemists, formulation technologists, and quality managers trained to GMP standards 

• Raw material ecosystem: India’s chemical and botanical raw material supply base — including ingredients for Ayurvedic-inspired Cosmetics, natural botanicals, and organic actives — provides domestic sourcing opportunities that reduce supply chain risk 

The End-to-End Setup with CliniExperts  

CliniExperts provides global Manufacturers with an integrated regulatory-to-commercial setup pathway for India manufacturing. The service covers: 

• Regulatory feasibility assessment: evaluating whether the product formulation, intended manufacturing model (own facility vs. contract), and target product categories are aligned with the Indian regulatory framework 

• SLA manufacturing license support: COS-5/COS-6 preparation, GMP gap assessment, layout plan review, and SLA liaison 

• Contract manufacturer identification: where the loan license (COS-9) model is appropriate, network of SLA-licensed Cosmetic manufacturers provides qualified partner options 

• India entity setup: company incorporation, GST registration, and importer/exporter code (IEC) — the legal prerequisites for Cosmetic manufacturing or import operations in India 

• Ongoing compliance management: PAC filing, license renewal, BIS compliance monitoring, and regulatory update tracking through CosmoAlly 

Table 1

Key Takeaways 

• India is an increasingly viable Cosmetic manufacturing hub — for domestic supply, regional export, and as a Make in India platform 

• The COS-9 loan license model provides a low-risk, regulatory-sanctioned contract manufacturing entry point for global Manufacturers 

• State Licensing Authorities issue manufacturing licenses; CDSCO remains relevant for novel ingredient approvals and market surveillance 

• BIS standards provide a quality infrastructure baseline that supports both India-market compliance and export-market positioning 

• An integrated regulatory-to-commercial setup — covering entity establishment, SLA licensing, manufacturing partner identification, and ongoing compliance — is available through CliniExperts